Blog
RSS FeedPosted by Michael Wonder on 09 Aug 2021
Competition from biosimilars drives price reductions for biologics in the French single payer health system
6 August 2021 - France has a single payer health insurance system that has the authority to impose pharmaceutical price reductions ...
Posted by Michael Wonder on 24 Mar 2021
The contribution of French patient and consumer groups to health technology assessments over a 2 year period: an observational retrospective study
22 March 2021 - In 2017, The French National Authority for Health created an open, online, systematic contribution process to enable ...
Posted by Michael Wonder on 15 Dec 2020
Vaccination strategy against SARS-Cov-2
15 December 2020 - Intermediate recommendations on the methods of implementing vaccination. ...
Posted by Michael Wonder on 04 Dec 2020
COVID-19 vaccine will be free of charge, 1 million inoculations set for January, French PM say
3 December 2020 - After the vaccination of an initial 1 million people in January an additional 14 million at ...
Posted by Michael Wonder on 17 Sep 2020
Transparency Commission publishes its opinion on Veklury
17 September 2020 - Gilead withdrew its request for the reimbursement of remdesivir in France on 31 August 2020. ...
Posted by Michael Wonder on 17 Jan 2020
France removes state funding for dementia drugs
17 January 2020 - The first country in Europe to act on concerns over limited effectiveness. ...
Posted by Michael Wonder on 06 Dec 2019
As Trump looks overseas for drug pricing ideas, one expert says France has some useful approaches
3 December 2019 - As the U.S. grapples with rising costs for prescription medicines, the Trump administration has floated a proposal ...
Posted by Michael Wonder on 03 Dec 2019
Could or should we use MCDA in the French HTA process?
3 December 2019 - Over the last decade, an increasing literature has been highlighting the benefits of introducing multi-criteria decision analysis ...
Posted by Michael Wonder on 20 Nov 2019
French Authorities approve national reimbursement of Orkambi (lumacaftor/ivacaftor) for eligible people ages two and older with cystic fibrosis
20 November 2019 - Vertex Pharmaceuticals today announced that the French Authorities (Comité économique des produits de santé, or CEPS) ...
Posted by Michael Wonder on 01 May 2019
The French solution to US drug prices
30 April 2019 - In June 1974, I rented a room in a lovely bungalow in the village of Vallauris in ...
Posted by Michael Wonder on 16 Dec 2018
Transparency Commission publishes its opinion for Kymriah
14 December 2018 - Opinion published following an examination of written submissions on 12 December 2018. ...
Posted by Michael Wonder on 09 Dec 2018
Transparency Commission publishes its opinion for Yescarta
7 December 2018 - Opinion published following an examination of written submissions on 5 December 2018. ...
Posted by Michael Wonder on 17 Oct 2018
Lojuxta to be reimbursed in France
17 October 2018 - Amryt's lead commercial product now available in all five of the EU's largest markets ...
Posted by Michael Wonder on 03 Oct 2018
Axumin (fluciclovine (18F)) receives positive recommendation from Transparency Committee of the French HAS for use in PET imaging of suspected recurrent prostate cancer
2 October 2018 - Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the Transparency Committee of ...
Posted by Michael Wonder on 03 Sep 2018
Agenda for September 5 TC meeting
3 September 2018 - HAS has posted the agenda for the next scheduled TC meeting. ...